Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase

Animals Antineoplastic Agents / adverse effects Cell Line, Tumor Disease Models, Animal Female Humans Immunologic Factors / adverse effects Liver / drug effects Lymphoma / pathology Mice Phosphatidylinositol 3-Kinases / metabolism Phosphoinositide-3 Kinase Inhibitors / adverse effects Pyrazoles / adverse effects Pyrimidines / adverse effects Pyrrolidines / adverse effects Xenograft Model Antitumor Assays

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
07 2020
Historique:
received: 21 02 2020
accepted: 20 04 2020
pubmed: 30 4 2020
medline: 13 11 2020
entrez: 30 4 2020
Statut: ppublish

Résumé

The clinical use of first-generation phosphoinositide 3-kinase (PI3K)

Identifiants

DOI: 10.1124/jpet.120.265538 PMID: 32345620
pubmed: 32345620
pii: jpet.120.265538
doi: 10.1124/jpet.120.265538
doi:

Substances chimiques

Antineoplastic Agents 0
Immunologic Factors 0
Phosphoinositide-3 Kinase Inhibitors 0
Pyrazoles 0
Pyrimidines 0
Pyrrolidines 0
parsaclisib OS7097575K

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-222

Informations de copyright

Copyright © 2020 by The Author(s).

Auteurs

Niu Shin (N)

Incyte Research Institute, Wilmington, Delaware nshin@incyte.com.

Matthew Stubbs (M)

Incyte Research Institute, Wilmington, Delaware.

Holly Koblish (H)

Incyte Research Institute, Wilmington, Delaware.

Eddy W Yue (EW)

Incyte Research Institute, Wilmington, Delaware.

Maxim Soloviev (M)

Incyte Research Institute, Wilmington, Delaware.

Brent Douty (B)

Incyte Research Institute, Wilmington, Delaware.

Kathy He Wang (KH)

Incyte Research Institute, Wilmington, Delaware.

Qian Wang (Q)

Incyte Research Institute, Wilmington, Delaware.

Mingming Gao (M)

Incyte Research Institute, Wilmington, Delaware.

Patricia Feldman (P)

Incyte Research Institute, Wilmington, Delaware.

Gengjie Yang (G)

Incyte Research Institute, Wilmington, Delaware.

Leslie Hall (L)

Incyte Research Institute, Wilmington, Delaware.

Michael Hansbury (M)

Incyte Research Institute, Wilmington, Delaware.

Sybil O'Connor (S)

Incyte Research Institute, Wilmington, Delaware.

Lynn Leffet (L)

Incyte Research Institute, Wilmington, Delaware.

Robert Collins (R)

Incyte Research Institute, Wilmington, Delaware.

Kamna Katiyar (K)

Incyte Research Institute, Wilmington, Delaware.

Xin He (X)

Incyte Research Institute, Wilmington, Delaware.

Paul Waeltz (P)

Incyte Research Institute, Wilmington, Delaware.

Paul Collier (P)

Incyte Research Institute, Wilmington, Delaware.

Jin Lu (J)

Incyte Research Institute, Wilmington, Delaware.

Yun-Long Li (YL)

Incyte Research Institute, Wilmington, Delaware.

Yanlong Li (Y)

Incyte Research Institute, Wilmington, Delaware.

Phillip C C Liu (PCC)

Incyte Research Institute, Wilmington, Delaware.

Timothy Burn (T)

Incyte Research Institute, Wilmington, Delaware.

Maryanne Covington (M)

Incyte Research Institute, Wilmington, Delaware.

Sharon Diamond (S)

Incyte Research Institute, Wilmington, Delaware.

Dana Shuey (D)

Incyte Research Institute, Wilmington, Delaware.

Alan Roberts (A)

Incyte Research Institute, Wilmington, Delaware.

Swamy Yeleswaram (S)

Incyte Research Institute, Wilmington, Delaware.

Greg Hollis (G)

Incyte Research Institute, Wilmington, Delaware.

Brian Metcalf (B)

Incyte Research Institute, Wilmington, Delaware.

Wenqing Yao (W)

Incyte Research Institute, Wilmington, Delaware.

Reid Huber (R)

Incyte Research Institute, Wilmington, Delaware.

Andrew Combs (A)

Incyte Research Institute, Wilmington, Delaware.

Robert Newton (R)

Incyte Research Institute, Wilmington, Delaware.

Peggy Scherle (P)

Incyte Research Institute, Wilmington, Delaware.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Système digestif › Foie › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Phosphatidylinositol 3-kinases › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs des phosphoinositide-3 kinases › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrrolidines › Parsaclisib Is a Next-Generation...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Parsaclisib Is a Next-Generation...